secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2026-09-09T20:10:18+00:00
Accession:  0001104659-26-106312
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics appoints Joseph Truitt to board; CNTY-813 IND on track for Q4 2026
--------------------------------------------------------------------------------

- Joseph Truitt appointed to board effective Sept 9, 2026; serves as Class I director, term to 2028 annual meeting.
- Truitt is CEO of iECURE; receives initial option grant of 148,000 shares vesting over 36 months and $40,000 annual retainer.
- CNTY-813 iPSC-derived islet replacement for T1D on track for IND submission in Q4 2026 after FDA pre-IND alignment.
- CNTY-308 CD19-targeted CAR-iT therapy expected to enter clinic in 2026; both use Allo-Evasion 5.0 platform.
- Truitt previously CEO of BioSpecifics and Achillion; also chairman of Larimar Therapeutics (LRMR).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465926106312/0001104659-26-106312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465926106312/tm2625030d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-106312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer